Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -3.38% and Operating profit at -56.73% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 5.85% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -3.38% and Operating profit at -56.73% over the last 5 years
3
The company has declared negative results for the last 4 consecutive quarters
4
With ROE of 1.52%, it has a fair valuation with a 0.33 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 648 Million (Small Cap)
22.00
NA
0.91%
-0.45
0.11%
0.36
Revenue and Profits:
Net Sales:
87 Million
(Quarterly Results - Sep 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
39.89%
0%
39.89%
6 Months
39.58%
0%
39.58%
1 Year
59.96%
0%
59.96%
2 Years
-1.54%
0%
-1.54%
3 Years
-38.32%
0%
-38.32%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Caina Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.38%
EBIT Growth (5y)
-56.73%
EBIT to Interest (avg)
89.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
0.21
Tax Ratio
4.45%
Dividend Payout Ratio
57.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.25%
ROE (avg)
5.85%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
0.33
EV to EBIT
-55.88
EV to EBITDA
-4.31
EV to Capital Employed
-0.24
EV to Sales
-0.67
PEG Ratio
NA
Dividend Yield
0.99%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
1.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
86.50
97.20
-11.01%
Operating Profit (PBDIT) excl Other Income
-4.40
31.40
-114.01%
Interest
0.30
0.00
Exceptional Items
-0.80
-0.40
-100.00%
Consolidate Net Profit
-1.40
24.30
-105.76%
Operating Profit Margin (Excl OI)
-50.30%
208.70%
-25.90%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -11.01% vs -16.57% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -105.76% vs -41.30% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
384.70
409.90
-6.15%
Operating Profit (PBDIT) excl Other Income
64.30
123.50
-47.94%
Interest
0.40
0.10
300.00%
Exceptional Items
2.50
8.40
-70.24%
Consolidate Net Profit
52.30
112.60
-53.55%
Operating Profit Margin (Excl OI)
61.20%
222.30%
-16.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -6.15% vs -11.56% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -53.55% vs -30.45% in Dec 2023
About Caina Technology Co., Ltd. 
Caina Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






